Current/ Expected Orderbook/ Pending Orders?

The discussion on the order book specifically highlights that the new products are contributing approximately 70% to the order book on an annualized average basis. For example, Quarter 1 bookings for Ronfen are around Rs. 70 crores, and Quarter 2 is expected to be higher due to seasonality. CTPR contributes roughly Rs. 20 crores in bookings. The total revenue posted is around Rs. 600 crores, with major contributions from products like Ronfen, CTPR, AXEMAN, Warden, Tombo, Amito, and Propique. The company emphasizes that most bookings and revenue growth are driven by these new and specialized pr

Any current/future new fundraising through debt or equity?

Currently, Best Agrolife Limited is managing its CAPEX and operational funding through internal accruals, supported by healthy EBITDA margins and efficient working capital management. As stated by Sanjeev Kharbanda, so far, the company has been able to fund growth and CAPEX through internal sources without the need for debt. However, as the company approaches Greenfield project expansions aligned with its revenue growth targets, it anticipates exploring additional funding options. This implies that in the near future, Best Agrolife may consider raising debt or equity to support larger scale

Any current/future capex/capital investment/strategic investment?

Best Agrolife has planned an overall CAPEX of around Rs. 200 crores primarily for: - Capacity enhancement - Backward integration to support market demand - Investment in R&D and market footprint expansion Actual cash outflow for CAPEX for the current financial year is expected to be around Rs. 100-150 crores, with some spillover to next year. A separate registration budget of around Rs. 50 crores is allocated for export development, product registration, and market studies. The company is exploring green energy initiatives, having signed a 3 MW solar power purchase agreement to reduce en

Future growth expectations in sales/revenue/volumes?

Best Agrolife targets approximately 30% revenue growth for FY24, building on Q1's robust 32% YoY growth. Q2 and Q3 are expected to be stronger quarters due to seasonal demand, especially for products like Ronfen. New product launches contribute around 70% of annualized revenue, expected to drive further growth. The company aims to maintain a 20% EBITDA margin alongside the revenue growth. Sales projections include Ronfen reaching Rs. 350-400 crores for the full year, with significant contributions from CTPR and other key products like Warden, Bestie, Bestline, and Pymax. Investment i

IN US

Sale is live|00:00:00left today

Best Agrolife LtdQ2 FY23Fertilizers & Agrochemicals

Best Agrolife Ltd Q2 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹15.5P/E: 28.8Market Cap: ₹697 CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Best Agrolife targets approximately 30% revenue growth for FY24, building on Q1's robust 32% YoY growth.
→Q2 and Q3 are expected to be stronger quarters due to seasonal demand, especially for products like Ronfen.
→New product launches contribute around 70% of annualized revenue, expected to drive further growth.
→The company aims to maintain a 20% EBITDA margin alongside the revenue growth.
→Sales projections include Ronfen reaching Rs. 350-400 crores for the full year, with significant contributions from CTPR and other key products like Warden, Bestie, Bestline, and Pymax.
→Investment in capacity enhancement and backward integration with Rs. 200 crores CAPEX will support volume growth.
→Export strategy planned for FY25 aims to tap into international markets, adding to future growth.
→Overall, Best Agrolife is confident of sustaining growth through specialized patented products and expanding market presence.

Margin guidance

Category 3

- The company targets approximately 30% top-line growth over the previous year, maintaining robust revenue momentum. - EBITDA margin guidance is to sustain around 20%, reflecting a focus on profitability amid market challenges. - Management expects continued improvement in revenue driven by specialized, patented, and branded products, with newer launches contributing significantly in Q2 and Q3. - CAPEX of Rs. 200 crores is planned for capacity expansion and backward integration, supporting growth. - The company is optimistic about crossing Rs. 1,000 crore revenue in the near term fueled by product launches like Ronfen and CTPR. - Profit After Tax (PAT) showed a 124% YoY increase in Q1 FY24; growth is expected to continue with a focus on margins and operational efficiency. - Export plans from FY25 onward are expected to add incremental growth opportunities. Overall, Best Agrolife aims for sustained double-digit growth in earnings supported by innovative product mix and efficient cost management.

3 more insights locked — sign up free to unlock

Fundraise plans

→Currently, Best Agrolife Limited is managing its CAPEX and operational funding through internal accruals, supported by healthy EBITDA margins and efficient working capital management.
→As stated by Sanjeev Kharbanda, so far, the company has been able to fund growth and CAPEX through internal sources without the need for debt.
→However, as the company approaches Greenfield project expansions aligned with its revenue growth targets, it anticipates exploring additional funding options.
→This implies that in the near future, Best Agrolife may consider raising debt or equity to support larger scale expansions but no concrete plans or timelines were disclosed during the call.

Order book

Yes

→The discussion on the order book specifically highlights that the new products are contributing approximately 70% to the order book on an annualized average basis.
→For example, Quarter 1 bookings for Ronfen are around Rs. 70 crores, and Quarter 2 is expected to be higher due to seasonality.
→CTPR contributes roughly Rs. 20 crores in bookings.
→The total revenue posted is around Rs. 600 crores, with major contributions from products like Ronfen, CTPR, AXEMAN, Warden, Tombo, Amito, and Propique.
→The company emphasizes that most bookings and revenue growth are driven by these new and specialized products within their portfolio.
→Overall, the order book reflects strong demand especially from new patented and specialized formulations.

Capex plans

Yes

→Best Agrolife has planned an overall CAPEX of around Rs. 200 crores primarily for:
→ - Capacity enhancement
→ - Backward integration to support market demand
→ - Investment in R&D and market footprint expansion
→Actual cash outflow for CAPEX for the current financial year is expected to be around Rs. 100-150 crores, with some spillover to next year.
→A separate registration budget of around Rs. 50 crores is allocated for export development, product registration, and market studies.
→The company is exploring green energy initiatives, having signed a 3 MW solar power purchase agreement to reduce energy costs by 33% and lower carbon footprint (~4,000 tonnes annually).
→Future funding for expansion may require additional debt once the company scales up to Greenfield projects, though currently CAPEX is funded through internal accruals.

How does Best Agrolife Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature

1Best Agrolife Ltd

Rev 2Mar 3

See full Fertilizers & Agrochemicals sector rankings

Want more stocks like Best Agrolife Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio